United Therapeutics Co. (UTHR) Shares Sold by Tobam

Tobam reduced its stake in shares of United Therapeutics Co. (NASDAQ:UTHR) by 19.8% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 58,935 shares of the biotechnology company’s stock after selling 14,528 shares during the period. Tobam owned about 0.13% of United Therapeutics worth $7,978,000 as of its most recent filing with the SEC.

A number of other institutional investors have also modified their holdings of the stock. Ladenburg Thalmann Financial Services Inc. increased its position in shares of United Therapeutics by 11.3% in the fourth quarter. Ladenburg Thalmann Financial Services Inc. now owns 717 shares of the biotechnology company’s stock valued at $104,000 after buying an additional 73 shares during the last quarter. Focused Wealth Management Inc acquired a new position in shares of United Therapeutics during the fourth quarter valued at about $115,000. Advisory Services Network LLC acquired a new position in shares of United Therapeutics during the first quarter valued at about $147,000. Daiwa Securities Group Inc. increased its position in shares of United Therapeutics by 17.4% in the first quarter. Daiwa Securities Group Inc. now owns 1,350 shares of the biotechnology company’s stock valued at $183,000 after buying an additional 200 shares during the last quarter. Finally, Campbell & CO Investment Adviser LLC acquired a new position in shares of United Therapeutics during the first quarter valued at about $204,000.

Institutional Ownership by Quarter for United Therapeutics (NASDAQ:UTHR)

United Therapeutics Co. (NASDAQ:UTHR) traded up 0.37% during midday trading on Friday, hitting $121.64. The stock had a trading volume of 496,443 shares. United Therapeutics Co. has a 52 week low of $97.52 and a 52 week high of $169.89. The company’s 50-day moving average price is $122.63 and its 200 day moving average price is $138.59. The company has a market capitalization of $5.48 billion, a PE ratio of 8.54 and a beta of 1.42.

United Therapeutics (NASDAQ:UTHR) last announced its quarterly earnings results on Wednesday, April 26th. The biotechnology company reported $3.89 EPS for the quarter, beating the Zacks’ consensus estimate of $3.12 by $0.77. United Therapeutics had a return on equity of 41.78% and a net margin of 44.40%. The company had revenue of $370.50 million during the quarter, compared to analysts’ expectations of $399.59 million. During the same period in the prior year, the company earned $3.02 EPS. United Therapeutics’s revenue was up .4% compared to the same quarter last year. On average, analysts expect that United Therapeutics Co. will post $14.42 EPS for the current year.

ILLEGAL ACTIVITY WARNING: This story was first published by Transcript Daily and is owned by of Transcript Daily. If you are reading this story on another site, it was illegally copied and reposted in violation of U.S. & international copyright law. The correct version of this story can be read at https://transcriptdaily.com/2017/05/20/united-therapeutics-co-uthr-shares-sold-by-tobam.html.

Several equities analysts have issued reports on the company. Cowen and Company reiterated a “hold” rating and issued a $121.00 price objective on shares of United Therapeutics in a research report on Wednesday, April 26th. Jefferies Group LLC reiterated an “underperform” rating and issued a $105.00 price objective (down previously from $116.00) on shares of United Therapeutics in a research report on Friday, April 28th. Zacks Investment Research downgraded United Therapeutics from a “buy” rating to a “hold” rating in a research report on Monday, February 27th. Oppenheimer Holdings Inc. reiterated a “buy” rating on shares of United Therapeutics in a research report on Monday, April 3rd. Finally, Wedbush reiterated an “outperform” rating and issued a $229.00 price objective on shares of United Therapeutics in a research report on Friday, January 27th. Three investment analysts have rated the stock with a sell rating, eight have given a hold rating and two have given a buy rating to the stock. The stock presently has an average rating of “Hold” and an average price target of $135.17.

In related news, CEO Martine A. Rothblatt sold 1,259 shares of the firm’s stock in a transaction on Thursday, May 11th. The stock was sold at an average price of $122.00, for a total transaction of $153,598.00. Following the completion of the transaction, the chief executive officer now directly owns 1,399 shares of the company’s stock, valued at approximately $170,678. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CEO Martine A. Rothblatt sold 1,208 shares of the firm’s stock in a transaction on Thursday, February 23rd. The stock was sold at an average price of $145.16, for a total value of $175,353.28. Following the transaction, the chief executive officer now directly owns 1,348 shares of the company’s stock, valued at $195,675.68. The disclosure for this sale can be found here. Insiders sold a total of 16,838 shares of company stock valued at $2,235,646 over the last quarter. 7.50% of the stock is owned by corporate insiders.

United Therapeutics Company Profile

United Therapeutics Corporation is a biotechnology company. The Company is focused on the development and commercialization of products for the treatment of chronic and life-threatening conditions. The Company markets and sells four commercial therapies in the United States to treat pulmonary arterial hypertension (PAH): Remodulin (treprostinil) Injection; Tyvaso (treprostinil) Inhalation Solution (Tyvaso); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca).

12 Month Chart for NASDAQ:UTHR

Receive News & Ratings for United Therapeutics Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics Co. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply